Profile
NLSP VRTX REGN SGEN ARGX ALNY
Company Name NLS Pharmaceutics AG Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $4.20M $128.84B $64.28B $43.15B $39.39B $33.74B
Employees 0.01K 6.10K 15.16K 3.26K 1.60K 2.23K
CEO Mr. Alexander Zwyer M.B.A. Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc. Dr. Yvonne L. Greenstreet M.B.A., M.D.
Ratings
NLSP VRTX REGN SGEN ARGX ALNY
Quant Rating Score 2 2 4 3 3 1
Quant Rating Sell Sell Buy Neutral Neutral Strong Sell
Trading
NLSP VRTX REGN SGEN ARGX ALNY
Last Close $1.64 $424.99 $527.78 $228.74 $549.65 $251.15
High 52 $5.3 $516.74 $1201.76 $228.74 $671.75 $296.75
Low 52 $0.11 $396.64 $527.78 $228.74 $356.01 $146.93
Price vs. 52 Week High -69.06 % -17.76 % -56.08 % 0 % -18.18 % -15.37 %
Price vs. 52 Week Low 1390.91 % 7.15 % 0 % 0 % 54.39 % 70.93 %
Total Return
NLSP VRTX REGN SGEN ARGX ALNY
1 Month Return 21.47 % -10.62 % -3.41 % 0 % 0.63 % 10.99 %
3 Month Return -36.19 % -9.57 % -23.55 % 0 % -14.97 % -8.36 %
6 Month Return -58.38 % -17.76 % -36.29 % 0 % -7.78 % -9.47 %
9 Month Return 753.28 % -9.28 % -53.35 % 0 % 2.74 % -6.82 %
YTD Return -22.27 % 5.54 % -25.91 % 0 % -10.63 % 6.73 %
1 Year Return 1077.32 % 0.52 % -45.8 % 0 % 46.72 % 66.91 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NLSP VRTX REGN SGEN ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.15 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -766442.97 % -1.65 % 3.85 % -2.27 % -44.32 % -1.49 %
Dividend Per Share (TTM) - - 0.88 % - - -
Payout Ratio (TTM) - - 2.08 % - - -
Growth
NLSP VRTX REGN SGEN ARGX ALNY
Asset Growth -80.09 % -0.87 % -1.21 %
Gross Profit Growth - 10.25 % 22.93 %
Revenue Growth - 11.66 % 24.65 %
Revenue 3 Year - 45.6 % 91.56 %
Revenue 5 Year - 163.93 % 215.48 %
Revenue 10 Year - 1632.15 % 494.04 %
EBIT Growth 23.74 % -93.69 % 10.13 %
Net Income Growth 26.21 % -114.8 % 9.51 %
Net Income 3 Yeari Growth Per Share 46.3 % -122.89 % -763.59 %
Net Income 5 Yeari Growth Per Share 99.03 % -145.38 % -276.93 %
Net Income 10 Yeari Growth Per Share 43.58 % 33.84 % -624.16 %
Operating Income Growth 23.74 % -105.41 % 10.13 %
Operating Cash Flow Growth (CFG) 30.22 % -113.93 % 9.07 %
Operating 3 Year CFG -67.61 % -118.65 % -147.99 %
Operating 5 Year CFG 100 % -131.3 % -195.86 %
Operating 10 Year CFG 44.99 % 12.43 % -2622.09 %
EPS Growth 61.9 % -114.8 % 10.81 %
EPS Diluted Growth 61.9 % -114.97 % 10.81 %
Book Value Per Share -238.82 % -6.59 % -9.83 %
Share Holder 3 Year Equity Growth Per Share 87.59 % 62.6 % 33.72 %
Share Holder 5 Year Equity Growth Per Share 100 % 168.85 % 220.81 %
Share Holder 10 Year Equity Growth Per Share 64.68 % 1265.7 % 691.19 %
Dividend Per Share Growth - - -
Dividend 3 Year Growth Per Share - - -
Dividend 5 Year Growth Per Share - - -
Dividend 10 Year Growth Per Share - - -
Debt Growth - 116.42 % -23.28 %
Free Cash Flow Growth 30.22 % -124.1 % 3.67 %
Updated On 31 Dec 2023 31 Dec 2024 31 Dec 2022
Profitability
NLSP VRTX REGN SGEN ARGX ALNY
Gross Profit Margin TTM - 86.09 % 84.94 % 72.37 % 46.33 % 86.01 %
Return on Assets TTM -170.96 % -2.38 % 11.98 % -11.76 % 13.45 % -6.4 %
Return on Equity TTM 22.54 % -3.28 % 14.77 % -16.53 % 16.83 % -509.33 %
Return on Capital Employed TTM 31.54 % -1.3 % 11.35 % -16.87 % -0.31 % -3.68 %
Net Income Per EBT TTM 100 % -215.53 % 90.27 % 100.55 % 25990.14 % 75.89 %
EBT Per Ebit TTM 99.16 % -100.69 % 129.3 % 94.01 % -18.79 % 308.03 %
EBIT Per Revenue TTM - -2.24 % 27.37 % -36.09 % -0.77 % -4.91 %
Cash Flow To Debt Ratio TTM -89.45 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Receivables Turnover TTM - 6.84 2.53 1.98 2.46 5.62
Payables Turnover TTM - 3.71 3.01 1.54 1.83 3.37
Inventory Turnover TTM 11408 1.27 0.66 0.65 2.93 5.01
Fixed Asset Turnover TTM - 425.82 % 300.07 % 256.83 % 5106.8 % 337.41 %
Asset Turnover TTM - 48.84 % 37.52 % 34.46 % 35.83 % 55.72 %
Operating Cash Flow Per Share TTM -0.04 -1.91 37.05 -1.12 -1.07 -0.35
Free Cash Flow Per Share TTM -0.04 -3.07 28.3 -1.62 -1.09 -0.58
Cash Per Share TTM 1.32 % 2375.11 % 7825.12 % 657.5 % 4597.04 % 2024.29 %
Operating Cash Flow Sales Ratio TTM - -4.48 % 28.06 % -16.85 % -3.54 % -1.92 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 160.43 % 76.4 % 144.14 % 102.26 % 167.11 %
Cash Flow Coverage Ratios TTM -89.45 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Price To Free Cash Flows Ratio TTM -2.74 -163.02 21.29 -141.85 -505.86 -447.57
Price To Operating Cash Flows Ratio TTM -46.52 -261.97 16.35 -203.89 -601.06 -745.64
Price Cash Flow Ratio TTM -46.52 -261.97 16.35 -203.89 -601.06 -745.64
Income Statement (TTM)
NLSP VRTX REGN SGEN ARGX ALNY
Revenue $0B $11.02B $14.2B $1.96B $2.19B $2.25B
Gross Profit $-0B $9.49B $12.23B $1.55B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 86.13% 79.1% 89.62% 85.62%
EBITDA $-0.01B $0.48B $5.32B $-0.62B $0B $-0.18B
Net Income $-0.01B $-0.54B $4.41B $-0.61B $0.83B $-0.28B
EPS Diluted -0.32 -2.08 38.34 -3.3 12.78 -2.16
Balance Sheet (MRQ)
NLSP VRTX REGN SGEN ARGX ALNY
Long Term Debt $0B $1.66B $1.98B $0.04B $0.03B $0B
Total Liabilities $0.01B $6.12B $8.41B $0.87B $0.7B $4.17B
Total Equity $-0.01B $16.41B $29.35B $2.8B $5.5B $0.07B
Total Investments $0B $6.65B $15.42B $1.42B $1.93B $1.73B
Total Debt $0B $1.75B $2.7B $0.04B $0.04B $1.3B
Total Assets $0B $22.53B $37.76B $3.67B $6.2B $4.3B
Cash Flow Statement (TTM)
NLSP VRTX REGN SGEN ARGX ALNY
Net Income $-0.01B $-0.54B $4.41B $-0.61B $0.8B $-0.28B
Inventory $0B $-0.52B $-0.62B $-0.23B $-0.09B $0.01B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.42B $-0.45B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.76B $-0.08B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.31
ABCL AbCellera Biologics Inc. 2.03
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.27
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 0.9801
ABPWW 0.02
ABSI Absci Corporation 2.75
ABUS Arbutus Biopharma Corporation 3.23
ABVC ABVC BioPharma, Inc. 1.21
ABVX Abivax SA American Depositary Shares 6.71
ACAD ACADIA Pharmaceuticals Inc. 17.44
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.6099
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.35
ACIU AC Immune SA 1.68
ACLX Arcellx, Inc. 57.55
Unlock